Fieldview Capital Management LLC Takes $1.73 Million Position in Moderna, Inc. $MRNA

Fieldview Capital Management LLC bought a new stake in Moderna, Inc. (NASDAQ:MRNA) during the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 58,752 shares of the company’s stock, valued at approximately $1,733,000.

A number of other hedge funds have also recently modified their holdings of the stock. Financial Gravity Asset Management Inc. grew its position in shares of Moderna by 11.7% in the 4th quarter. Financial Gravity Asset Management Inc. now owns 78,537 shares of the company’s stock valued at $2,316,000 after buying an additional 8,212 shares during the last quarter. Landscape Capital Management L.L.C. grew its position in shares of Moderna by 97.6% in the 4th quarter. Landscape Capital Management L.L.C. now owns 22,347 shares of the company’s stock valued at $659,000 after buying an additional 11,037 shares during the last quarter. FORA Capital LLC purchased a new position in shares of Moderna in the 4th quarter valued at $760,000. Stifel Financial Corp grew its position in shares of Moderna by 290.8% in the 4th quarter. Stifel Financial Corp now owns 57,253 shares of the company’s stock valued at $1,688,000 after buying an additional 42,604 shares during the last quarter. Finally, Hudson Bay Capital Management LP grew its position in shares of Moderna by 344.7% in the 4th quarter. Hudson Bay Capital Management LP now owns 244,594 shares of the company’s stock valued at $7,213,000 after buying an additional 189,594 shares during the last quarter. 75.33% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms recently commented on MRNA. Morgan Stanley set a $33.00 target price on shares of Moderna in a research report on Friday, May 1st. Piper Sandler increased their target price on shares of Moderna from $63.00 to $69.00 and gave the company an “overweight” rating in a research report on Monday, February 23rd. Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $45.00 target price on shares of Moderna in a research report on Tuesday, February 17th. Bank of America increased their target price on shares of Moderna from $32.00 to $34.00 and gave the company an “underperform” rating in a research report on Monday, June 8th. Finally, UBS Group reissued a “neutral” rating on shares of Moderna in a research report on Tuesday, May 26th. Two investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and five have issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Reduce” and an average target price of $36.60.

Moderna Stock Performance

Shares of Moderna stock opened at $49.91 on Monday. Moderna, Inc. has a 1 year low of $22.28 and a 1 year high of $59.55. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.35 and a current ratio of 2.41. The company has a market capitalization of $19.80 billion, a P/E ratio of -6.12 and a beta of 1.05. The company’s fifty day moving average is $49.61 and its two-hundred day moving average is $44.17.

Moderna (NASDAQ:MRNA) last issued its earnings results on Friday, May 1st. The company reported ($3.40) earnings per share for the quarter, missing the consensus estimate of ($3.02) by ($0.38). The firm had revenue of $389.00 million during the quarter, compared to analysts’ expectations of $236.37 million. Moderna had a negative net margin of 143.55% and a negative return on equity of 26.64%. The firm’s revenue was up 260.2% on a year-over-year basis. During the same period in the previous year, the firm earned ($2.52) EPS. Analysts forecast that Moderna, Inc. will post -6.51 earnings per share for the current year.

Insider Activity

In other news, President Stephen Hoge sold 53,336 shares of Moderna stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $48.40, for a total value of $2,581,462.40. Following the sale, the president owned 1,477,997 shares of the company’s stock, valued at $71,535,054.80. The trade was a 3.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Abbas Hussain sold 5,682 shares of Moderna stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $46.63, for a total transaction of $264,951.66. Following the completion of the sale, the director directly owned 12,066 shares in the company, valued at approximately $562,637.58. The trade was a 32.01% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 71,752 shares of company stock worth $3,453,843 in the last ninety days. 10.80% of the stock is currently owned by insiders.

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.